Limitations

There were several limitations in our study. Although quality-assessment results indicated the overall study quality was good, several trials had some risk of bias in their study design, as mentioned earlier. Publication bias always exists and is unavoidable in meta-analyses, and inverted funnel plots of our study indicated potential risks in outcomes of total complication and hospital stay. For infectious outcomes, different doses and kinds of antibiotic used before and after surgery may have caused heterogeneity across the trials. Although the preoperative prophylactic antibiotic was comparable in each separate trial, the intra- and postoperative antibiotic can only be used based on a certain situation of operation time and blood loss, while only half of the trials reported relevant data. SSI was also an important issue in the clinic, and CRC surgery as a clean-contaminated operation had a high risk of SSI,31 although the omega-3 group had a lower SSI incidence and no statistical difference was found. As Braga et al reported, about 25% of postoperative infection, especially wound infection, occurred after discharge,11 and longer follow-up to 1 month would be important for future study.


Continue Reading

CONCLUSION

Short-term omega-3 PUFAs were associated with reduced postoperative infectious complications, inflammatory cytokines, and hospital stay after CRC surgery. Due to heterogeneity and relatively small sample size, the optimal timing and route of administration deserve further longer follow-up study.

Disclosure

The authors report no conflicts of interest in this work.


Hai Xie,1 Yan-na Chang2

1Department of Emergency, The First Hospital of Lanzhou University, 2Department of Anesthesiology, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, People’s Republic of China 


References

1. Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203.

2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.

3. Gagnière J, Raisch J, Veziant J, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22(2):501–518.

4. Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int. 2014;2014:782890.

5. López PR, Escribano JA, Rodríguez-Cuéllar E, García IL, Mata EJ. Proyecto nacional para la gestión clínica de procesos asistenciales. Tratamiento quirúrgico del cáncer colorrectal. I. Aspectos generales [National project for the management of clinical processes: surgical treatment of colorectal cancer – I: general aspects]. Cir Esp. 2002;71(4):173–180. Spanish.

6. Hull MA. Omega-3 polyunsaturated fatty acids. Best Pract Res Clin Gastroenterol. 2011;25(4):547–554.

7. Pradelli L, Mayer K, Muscaritoli M, Heller AR. n-3 Fatty acid-enriched parenteral nutrition regimens in elective surgical and ICU patients: a meta-analysis. Crit Care. 2013;16(5):R184.

8. Zhang YF, Gao HF, Hou AJ, Zhou YH. Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death, and total mortality: a meta-analysis of randomized controlled trials. BMC Public Health. 2014;14:204.

9. Wei C, Hua J, Bin C, Klassen K. Impact of lipid emulsion containing fish oil on outcomes of surgical patients: systematic review of randomized controlled trials from Europe and Asia. Nutrition. 2010;26(5):474–481.

10. Chen B, Zhou Y, Yang P, Wan HW, Wu XT. Safety and efficacy of fish oil-enriched parenteral nutrition regimen on postoperative patients undergoing major abdominal surgery: a meta-analysis of randomized controlled trials. JPEN J Parenter Enteral Nutr. 2010;34(4):387–394.

11. Braga M, Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery. 2002;132(5):805–814.

12. Matsuda A, Furukawa K, Takasaki H, et al. Preoperative oral immune-enhancing nutritional supplementation corrects TH1/TH2 imbalance in patients undergoing elective surgery for colorectal cancer. Dis Colon Rectum. 2006;49(4):507–516.

13. Finco C, Magnanini P, Sarzo G, et al. Prospective randomized study on perioperative enteral immunonutrition in laparoscopic colorectal surgery. Surg Endosc. 2007;21(7):1175–1179.

14. Liang B, Wang S, Ye YJ, et al. Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients. World J Gastroenterol. 2008;14(15):2434–2439.

15. Horie H, Okada M, Kojima M, Nagai H. Favorable effects of preoperative enteral immunonutrition on a surgical site infection in patients with colorectal cancer without malnutrition. Surg Today. 2006;36(12):1063–1068.

16. Zhu MW, Tang DN, Hou J, et al. Impact of fish oil enriched total parenteral nutrition on elderly patients after colorectal cancer surgery. Chin Med J (Engl). 2012;125(2):178–181.

17. Aliyazicioglu T, Cantürk NZ, Şimşek T, Kolayli F, Çekmen M. Effects of standard and/or glutamine dipeptide and/or omega-3 fatty acid-supplemented parenteral nutrition on neutrophil functions, interleukin-8 level and length of stay-a double blind, controlled, randomised study. East Afr Med J. 2014;90(2):59–66.

18. Sorensen LS, Rasmussen HH, Aardestrup IV, et al. Rapid incorporation of ω-3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. JPEN J Parenter Enteral Nutr. 2014;38(5):617–624.

19. Sorensen LS, Thorlacius-Ussing O, Rasmussen HH, et al. Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B4 and leukotriene B5 production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. Nutrients. 2014;6(10):4043–4057.

20. Sorensen LS, Thorlacius-Ussing O, Schmidt EB, et al. Randomized clinical trial of perioperative omega-3 fatty acid supplements in elective colorectal cancer surgery. Br J Surg. 2014;101(2):33–42.

21. Ma CJ, Wu JM, Tsai HL, et al. Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patients. Nutr J. 2015;14:9.

22. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

23. Roulet M, Frascarolo P, Pilet M, Chapuis G. Effects of intravenously infused fish oil on platelet fatty acid phospholipid composition and on platelet function in postoperative trauma. JPEN J Parenter Enteral Nutr. 1997;21(5):296–301.

24. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut. 2014;61(4):135–149.

25. Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002;122(7):1763–1770.

26. Song GM, Tian X, Zhang L, et al. Immunonutrition support for patients undergoing surgery for gastrointestinal malignancy: preoperative, postoperative, or perioperative? A Bayesian network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(29):e1225.

27. Desai SV, Mcclave SA, Rice TW. Nutrition in the ICU: an evidence-based approach. Chest. 2014;145(5):1148–1157.

28. Bufo AJ, Feldman S, Daniels GA, Lieberman RC. Early postoperative feeding. Dis Colon Rectum. 1994;37(12):5–6.

29. Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg. 1999;177(3):203–208.

30. Tatsumi H, Ura H, Ikeda S, et al. Surgical influence on TH1/TH2 balance and monocyte surface antigen expression and its relation to infectious complications. World J Surg. 2003;27(5):522–528.

31. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–485.

Source: OncoTargets and Therapy.
Originally published December 9, 2016.